Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyBCBS Louisiana Optilume Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of LouisianaPolicy MA-244

    Optilume Device for Urethral Stricture and Benign Prostatic Hyperplasia

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy MA-244 alerts

    Get alerted when Policy MA-244 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of the Optilume Urethral drug-coated balloon for recurrent bulbar urethral stricture and the Optilume BPH Catheter System for lower urinary tract symptoms secondary to benign prostatic hyperplasia when applicable benefits and medical-necessity criteria are met.

    Policy Summary
    PayerBlue Cross Blue Shield of Louisiana
    PolicyOptilume Device for Urethral Stricture and Benign Prostatic Hyperplasia
    Policy CodePolicy MA-244
    Change TypeNo material change
    Effective DateJan 1, 202743d
    Last ReviewOct 20, 2026
    Next Review DateOct 1, 2027
    Key ActionBefore requesting coverage, document that benefits are available and that medical-necessity criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≤3 cmCovered stricture length
    2021Urethral DCB approval
    2023BPH Catheter approval
    Not coveredBPH Catheter coverage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    RequiredPrior authorization

    Coverage Criteria

    Optilume Urethral DCB coverage

    The Optilume Urethral drug-coated balloon may be eligible for coverage when ALL of the following are met.

    Covered recurrent bulbar urethral stricture

    • Patient population: Adult manAdult men
    • Stricture location: The stricture is located in the bulbar urethraBulbar urethra
    • Stricture length: The stricture is 3 cm or less in length≤3 cm
    • Recurrent disease after prior treatment: The stricture is recurrent and prior endoscopic treatment has failed, consisting of direct visual internal urethrotomy or dilationFailed prior DVIU or dilation
    • Infection status: There is no active urinary tract infectionNo active UTI

    Urethral DCB investigational uses

    The Optilume Urethral drug-coated balloon is considered investigational when the coverage criteria are not met or in any of the following circumstances.

    Investigational urethral stricture use

    • Anatomic location: Penile urethral stricturePenile urethra
    • Anatomic location: Prostatic urethral strictureProstatic urethra
    • Treatment status: First-time or primary treatmentPrimary treatment

    Optilume BPH Catheter System

    The Optilume BPH Catheter System is considered investigational.

    BPH indication: Treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia with the Optilume BPH Catheter System

    Available evidence is insufficient to determine improvement in the net health outcome.

    Urethral stricture evidence-supported population

    Evidence supports improvement in net health outcome for the described population.

    Recurrent bulbar urethral stricture evidence population: Individuals have recurrent anterior (bulbar) urethral stricture measuring 3 cm or less, have failed prior endoscopic treatment, and receive the Optilume Urethral drug-coated balloon.Stricture length ≤3 cm

    The evidence review states that the technology improves the net health outcome in this population.

    BPH evidence-insufficient population

    Evidence is insufficient to determine improvement in net health outcome.

    BPH evidence population: Individuals have moderate-to-severe lower urinary tract symptoms secondary to benign prostatic hyperplasia and receive the Optilume BPH Catheter System.Moderate-to-severe lower urinary tract symptoms

    The evidence review concludes that evidence is insufficient to determine improvement in the net health outcome.

    Medicare Advantage coverage framework

    Coverage review for Medicare Advantage members.

    Applicable Medicare and internal criteria: Established coverage criteria must be sought in applicable Medicare statutes, regulations, National Coverage Determinations, and Local Coverage Determinations. When Medicare coverage criteria are not fully established, internal coverage criteria may be developed and used as the policy's evidence-supported coverage standard.

    Refer to the Medicare Coverage Database to determine whether an NCD or LCD addresses the service.

    InterQual medical necessity review

    Utilization review process.

    InterQual screening and escalation: InterQual criteria may be used as a first-level screening tool to assess whether proposed services are clinically indicated and provided at the appropriate level. Cases meeting the criteria may be approved; cases not meeting the criteria are referred to the medical director for further evaluation.

    InterQual is used with the independent professional medical judgment of a qualified health care provider.

    Use of the Optilume devices is contraindicated in patients with known hypersensitivity to paclitaxel or structurally related compounds.

    The Optilume devices are contraindicated in the presence of an active urinary tract infection. For Optilume Urethral DCB coverage, documentation must establish that no active urinary tract infection is present.

    The Optilume Urethral DCB is considered investigational for penile or prostatic urethral strictures, first-time (primary) treatment, or repeated device use.

    The AUA conditional recommendation for drug-coated balloons is restricted to men with recurrent bulbar urethral strictures and does not extend to penile urethral strictures, which were not adequately assessed in the pivotal trial.

    The AUA states that repeated use of the Optilume drug-coated balloon is not recommended.

    Drug-coated balloons were not assessed in controlled trials for first-time treatment of anterior urethral stricture. Accordingly, the supporting recommendation is limited to recurrent bulbar urethral strictures rather than primary treatment.

    The Optilume Urethral DCB is considered investigational, and therefore not eligible for coverage, when the recurrent bulbar stricture criteria are not met. The evidence-supported population consists of individuals with a recurrent anterior, predominantly bulbar urethral stricture measuring ≤3 cm who have failed prior endoscopic treatment.

    Treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia with the Optilume BPH Catheter System is considered investigational. Available evidence is insufficient to determine that the technology improves the net health outcome in individuals with moderate-to-severe lower urinary tract symptoms secondary to BPH.

    Coding and Product Identifiers

    FDA regulatory and product identifiersmixed
    P210020FDA premarket approval identifier for the Optilume Urethral Drug-Coated Balloon
    P220029FDA premarket approval identifier for the Optilume BPH Catheter System
    QXBFDA product code for the Optilume BPH Catheter System
    CPTCPT
    52284
    52443
    HCPCSHCPCS
    C1889
    ICD-10 DiagnosisICD-10
    N40.1-N40.3
    N35.010-N35.016
    N35.111-N35.119
    N35.811-N35.819
    N35.911-N35.919
    Covered urethral stricture length threshold
    Covered populationAdult men with a recurrent bulbar urethral stricture
    Maximum stricture length3 cm or less
    Prior treatment requirementFailed prior endoscopic treatment, consisting of direct visual internal urethrotomy or dilation
    FDA-labeled BPH population age
    FDA-labeled populationMen aged 50 years and older
    IndicationObstructive urinary symptoms associated with benign prostatic hyperplasia

    Provider Actions and Utilization Review

    Prior Authorization

    Submit medical-necessity support

    Before requesting coverage, establish that benefits are available under the member’s contract and document that the medical-necessity criteria are met. For the Optilume Urethral DCB, documentation must support an adult man with a bulbar urethral stricture measuring 3 cm or less, recurrent after failed prior DVIU or dilation, and without active urinary tract infection.

    • Adult man
    • Bulbar urethral stricture
    • Stricture length of 3 cm or less
    • Recurrence after failed prior direct visual internal urethrotomy or dilation
    • Absence of active urinary tract infection
    Prior Authorization

    Prior authorization is required

    All codes listed in this medical policy require prior authorization to support appropriate utilization and alignment with current clinical guidelines. Obtain authorization before providing the service.

    Clinical Background

    Urethral stricture is a fibrotic narrowing of the urethral lumen that can obstruct urinary flow. This policy addresses the Optilume Urethral drug-coated balloon for recurrent anterior, predominantly bulbar strictures in adult men, including strictures measuring 3 cm or less after failed prior endoscopic treatment. It also addresses the Optilume BPH Catheter System for lower urinary tract symptoms secondary to benign prostatic hyperplasia; that use is considered investigational because the available evidence is insufficient to establish improvement in net health outcome.

    Definitions

    Definition of urethral stricture
    ConditionA fibrotic narrowing of the urethral lumen
    CauseScarring of the surrounding corpus spongiosum, also called spongiofibrosis
    Anterior urethraIncludes the meatus, fossa navicularis, penile urethra, and bulbar urethra
    Definition of Optilume Urethral drug-coated balloon
    Device typeA dual-lumen, over-the-wire balloon catheter
    CoatingPaclitaxel along the working length of the semi-compliant balloon
    Function
    Policy Summary
    PayerBlue Cross Blue Shield of Louisiana
    PolicyOptilume Device for Urethral Stricture and Benign Prostatic Hyperplasia
    Policy CodePolicy MA-244
    Change TypeNo material change
    Effective DateJan 1, 202743d
    Last ReviewOct 20, 2026
    Next Review DateOct 1, 2027
    Key ActionBefore requesting coverage, document that benefits are available and that medical-necessity criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Product IdentifiersProvider Actions and Utilization ReviewClinical BackgroundDefinitions
    Repeat device use: Repeated use of the deviceRepeated use
  1. Other failure of criteria: Urethral stricture treatment when the coverage criteria are not metCriteria not met
  2. DeviceOptilume BPH Catheter System
    AUA Symptom Index severity ranges
    MildAUA Symptom Index score of 7 or less
    ModerateAUA Symptom Index score of 8–19
    SevereAUA Symptom Index score of 20–35
    Recurrent anterior or bulbar urethral stricture length
    PopulationIndividuals with recurrent anterior (bulbar) urethral stricture
    Maximum length3 cm or less
    Prior treatmentFailed prior endoscopic treatment
    Documentation Required

    Document prior authorization for transition requests

    For a member changing health plans during an ongoing authorized course of treatment, the member or provider must provide documentation of the prior health plan’s authorization. The service must otherwise be covered under the Blue Advantage plan, provided under the same type of in-network benefit, and qualify for the applicable transition policy.

    • A 90-day transition period may apply.
    • Provide documentation of the authorization for the ongoing course of treatment.
    Denial Risk

    Avoid investigational or nonqualifying use

    Coverage is denied when the Optilume Urethral DCB is used for urethral stricture without meeting the policy criteria, including penile or prostatic urethral stricture, first-time primary treatment, or repeated device use. The Optilume BPH Catheter System is considered investigational for lower urinary tract symptoms secondary to BPH.

    • Penile urethral stricture
    • Prostatic urethral stricture
    • First-time or primary treatment
    • Repeated use of the device
    Denial Risk

    Check contraindications and active infection

    Use is contraindicated in patients with known hypersensitivity to paclitaxel or structurally related compounds or in the presence of active urinary tract infection. Screen for these conditions before treatment.

    • Known hypersensitivity to paclitaxel or structurally related compounds
    • Active urinary tract infection
    Denial Risk

    Confirm benefit availability and medical necessity

    Coverage is limited to services for which benefits are available under the member’s contract or certificate and applicable medical-necessity criteria are met. Verify benefit availability and medical necessity before submitting the request.

    Denial Risk

    BPH indication may be denied

    Optilume BPH Catheter System treatment may be denied because the evidence is insufficient to determine that it improves the net health outcome in individuals with moderate-to-severe lower urinary tract symptoms secondary to BPH.

    • Indication: lower urinary tract symptoms secondary to benign prostatic hyperplasia
    • Evidence population: moderate-to-severe symptoms
    Denial Risk

    Stay within the recurrent bulbar indication

    For urethral stricture treatment, the supporting guideline evidence is limited to recurrent bulbar urethral strictures. The recommendation does not extend to penile strictures, first-time anterior urethral stricture treatment, or repeated use of the device.

    • Use is restricted to recurrent bulbar urethral strictures.
    • Do not use for first-time treatment of anterior urethral stricture.
    • Repeated use is not recommended.
    Dilates the stricture and transfers paclitaxel to the urethral wall
    Definition of Optilume BPH Catheter System
    System componentsAn uncoated predilation catheter and a double-lobe, paclitaxel-coated dilation balloon
    Mechanical actionPerforms an anterior commissurotomy by separating the lateral prostatic lobes
    Drug deliveryDelivers paclitaxel locally to the prostatic urethra
    Definition of benign prostatic hyperplasia
    ConditionA common disorder of aging men arising from hyperplastic nodules in the transition zone and periurethral region of the prostate
    Anatomic effectProstatic enlargement can produce bladder outlet obstruction
    SymptomsLower urinary tract symptoms may include weak stream, hesitancy, straining, intermittency, incomplete emptying, frequency, urgency, and nocturia
    Definition of BPH
    AbbreviationBPH
    Full termBenign prostatic hyperplasia
    Clinical contextA condition associated with lower urinary tract symptoms and possible bladder outlet obstruction
    Definition of DVIU
    AbbreviationDVIU
    Full termDirect visual internal urethrotomy
    Policy contextA prior endoscopic treatment that may have failed before covered Optilume Urethral DCB treatment
    Definition of medically necessary or medical necessity
    PurposeHealth care services, treatment, procedures, equipment, drugs, devices, items, or supplies provided to prevent, evaluate, diagnose, or treat an illness, injury, disease, or its symptoms
    Clinical standardConform to nationally accepted standards of medical practice and be clinically appropriate in type, frequency, extent, level of care, site, and duration
    Cost and convenienceAre effective, not primarily for personal comfort or convenience, and no more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results
    Definition of nationally accepted standards of medical practice
    Evidence baseCredible scientific evidence published in peer-reviewed medical literature and generally recognized by the relevant medical community
    Professional guidancePhysician specialty society recommendations and the views of physicians practicing in relevant clinical areas
    Additional considerationsOther relevant factors may also be considered